WallStreetZenWallStreetZen

NYSEMKT: CYBN
Cybin Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CYBN

Based on 1 analyst offering 12 month price targets for Cybin Inc

Min Forecast
$70.00+1,053.21%
Avg Forecast
$70.00+1,053.21%
Max Forecast
$70.00+1,053.21%

Should I buy or sell CYBN stock?

Based on 1 analyst offering ratings for Cybin Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CYBN's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates CYBN as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their CYBN stock forecasts and price targets.

CYBN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-07-08

1 of 1

Forecast return on equity

Is CYBN forecast to generate an efficient return?

Company
-20.56%
Industry
247.01%
Market
230.21%
CYBN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CYBN forecast to generate an efficient return on assets?

Company
-14.8%
Industry
98.7%
CYBN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CYBN earnings per share forecast

What is CYBN's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$4.49
Avg 2 year Forecast
-$3.01
Avg 3 year Forecast
-$0.99

CYBN revenue forecast

What is CYBN's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$16.2M
Avg 3 year Forecast
$94.6M

CYBN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CYBN$5.95$70.00+1,076.47%Strong Buy
SPRO$2.43N/AN/A
ENTX$3.04N/AN/A
NKTX$1.95$12.00+515.38%Strong Buy
ACTU$6.46$20.00+209.60%Strong Buy
View Top Biotech Stocks

Cybin Stock Forecast FAQ

Is Cybin Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NYSEMKT: CYBN) stock is to Strong Buy CYBN stock.

Out of 1 analyst, 1 (100%) are recommending CYBN as a Strong Buy, 0 (0%) are recommending CYBN as a Buy, 0 (0%) are recommending CYBN as a Hold, 0 (0%) are recommending CYBN as a Sell, and 0 (0%) are recommending CYBN as a Strong Sell.

If you're new to stock investing, here's how to buy Cybin stock.

What is CYBN's earnings growth forecast for 2026-2028?

(NYSEMKT: CYBN) Cybin's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 36.45%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.21%.

Cybin's earnings in 2025 is -$89,727,007.On average, 5 Wall Street analysts forecast CYBN's earnings for 2026 to be -$103,430,257, with the lowest CYBN earnings forecast at -$112,293,404, and the highest CYBN earnings forecast at -$92,627,720. On average, 5 Wall Street analysts forecast CYBN's earnings for 2027 to be -$69,302,073, with the lowest CYBN earnings forecast at -$84,195,292, and the highest CYBN earnings forecast at -$52,471,767.

In 2028, CYBN is forecast to generate -$22,775,156 in earnings, with the lowest earnings forecast at -$100,221,742 and the highest earnings forecast at $60,491,901.

What is CYBN's revenue growth forecast for 2026-2028?

(NYSEMKT: CYBN) Cybin's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 107.7%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 26.15%.

Cybin's revenue in 2025 is $0.On average, 5 Wall Street analysts forecast CYBN's revenue for 2026 to be $0, with the lowest CYBN revenue forecast at $0, and the highest CYBN revenue forecast at $0. On average, 5 Wall Street analysts forecast CYBN's revenue for 2027 to be $372,376,564, with the lowest CYBN revenue forecast at $0, and the highest CYBN revenue forecast at $766,657,632.

In 2028, CYBN is forecast to generate $2,177,874,290 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $4,483,858,833.

What is CYBN's forecast return on assets (ROA) for 2026-2028?

(NYSEMKT: CYBN) forecast ROA is -14.8%, which is lower than the forecast US Biotechnology industry average of 109.29%.

What is CYBN's Price Target?

According to 1 Wall Street analyst that have issued a 1 year CYBN price target, the average CYBN price target is $70.00, with the highest CYBN stock price forecast at $70.00 and the lowest CYBN stock price forecast at $70.00.

The Wall Street analyst predicted that Cybin's share price could reach $70.00 by Jul 8, 2026. The average Cybin stock price prediction forecasts a potential upside of 1,076.47% from the current CYBN share price of $5.95.

What is CYBN's Earnings Per Share (EPS) forecast for 2026-2028?

(NYSEMKT: CYBN) Cybin's current Earnings Per Share (EPS) is -$4.34. On average, analysts forecast that CYBN's EPS will be -$4.49 for 2026, with the lowest EPS forecast at -$4.88, and the highest EPS forecast at -$4.02. On average, analysts forecast that CYBN's EPS will be -$3.01 for 2027, with the lowest EPS forecast at -$3.66, and the highest EPS forecast at -$2.28. In 2028, CYBN's EPS is forecast to hit -$0.99 (min: -$4.35, max: $2.63).

What is CYBN's forecast return on equity (ROE) for 2026-2028?

(NYSEMKT: CYBN) forecast ROE is -20.56%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.